The new molecules efficiently inhibit the fusion to the ACE/TMPRSS2-positive cells (H1299, lung carcinoma cells) with a 2-fold increase in potency compared to the initial natural compound (178). This evidence concerns the gene TMPRSS2 and lung carcinoma.